Incyte Corporation

This phase 3 trial tested whether adding parsaclisib to the standard drug ruxolitinib could better shrink enlarged spleens and ease symptoms in people with myelofibrosis. The study enrolled 252 participants but was terminated early, so we do not have full results. The combination…

This phase 2 study tested the drug pemigatinib in 111 people with advanced solid tumors that have specific FGFR gene mutations or translocations. The goal was to see if the drug could shrink tumors. The trial was terminated early, so the full results are not available.

This early-phase trial tested the safety of a drug called INCB059872 in 25 people with Ewing sarcoma that had returned or stopped responding to standard treatments. The study aimed to see if the drug was safe and whether it could shrink tumors. However, the trial was terminated e…

This phase 2 trial tested the drug pemigatinib in people with recurrent glioblastoma or other brain tumors that have specific changes in FGFR1-3 genes. Participants took a daily tablet for two weeks followed by one week off. The study aimed to see if the drug could shrink tumors,…

This study tested a combination of two drugs, tafasitamab and parsaclisib, in 54 adults with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL). The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminat…

This phase 2 study tested several drug combinations (retifanlimab, epacadostat, INCAGN02385, INCAGN02390) given before bladder removal surgery in 30 patients with muscle-invasive bladder cancer who could not take the standard chemo drug cisplatin. The trial was terminated early, …

This study tested whether adding itacitinib (an anti-inflammatory drug) to standard steroid treatment could help people with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. The trial enrolled 155 participants but was termi…

This study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.

This early-phase study tested an experimental drug called INCB081776, alone or combined with the immunotherapy retifanlimab, in 83 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and s…

This early-stage trial tested a combination of three drugs—azacitidine, pembrolizumab, and epacadostat—in 70 people with advanced solid tumors, including non-small cell lung cancer and colorectal cancer. The goal was to see if the combination was safe and could shrink tumors. How…

This early-phase study tested a combination of two drugs—atezolizumab (an immunotherapy) and epacadostat (an oral drug that helps the immune system attack cancer)—in 29 patients with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal wa…

This phase 3 study tested the drug parsaclisib in people with primary warm autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. The trial aimed to see if parsaclisib could improve hemoglobin levels and reduce fatigue compared to a placebo. Ho…

This early-phase study tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in 57 people with advanced solid tumors like head and neck or gastrointestinal cancers. The goal was to check safety, dosing, and early signs of effectiveness. The trial …

This phase 2 study tested whether adding itacitinib to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. The trial was stopped early after enrolling only 9 participants, so we cannot tell if the combination is safe or effect…

This study tested whether adding an experimental drug (INCB001158) to a standard therapy (daratumumab) could help people with multiple myeloma that returned or didn't respond to prior treatments. The trial enrolled 15 adults who had already tried at least 3 other therapies. The g…

This study looked at whether adding an immunotherapy drug (pembrolizumab) to a targeted therapy (pemigatinib) works better than the targeted therapy alone or standard care for people with advanced bladder cancer that has a specific gene change (FGFR3). The study was stopped early…

This study tested a drug called itacitinib combined with steroids to treat acute graft-versus-host disease (aGVHD) in children. aGVHD is a serious complication where donor immune cells attack the child's body after a stem cell transplant. The trial was stopped early after enrolli…

This study tested a combination of two drugs, ipilimumab and epacadostat, in people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if adding epacadostat to standard treatment improved survival. However, the study was stopped early f…

This study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib helps people with myelofibrosis whose spleen and symptoms haven't improved enough on ruxolitinib alone. The main goal was to see if the combination could shrink the spleen by at le…

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This early-phase study tested whether adding the drug itacitinib to standard anti-rejection medicines could help prevent graft-versus-host disease (GVHD) in people with blood cancers receiving a stem cell transplant. The study enrolled 84 participants and focused on safety and bl…

This study tested a new drug called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. It was open to those who needed blood transfusions or had anemia symptoms. The study aimed to find a safe dose and check for side effects, but it w…

This early-stage study tested a new drug called INCB062079 in 25 people with advanced liver cancer or other solid tumors that had spread. The main goal was to check the drug's safety and find the best dose. The study was stopped early, so results are limited.

This study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlar…

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This early-phase study tested the drug itacitinib in 23 people who developed bronchiolitis obliterans syndrome (a type of lung scarring) after a double lung transplant. The goal was to see if it could safely improve lung function. The study was terminated early, so results are li…

This study tested a prescription cream called ruxolitinib on adults with mild-to-moderate eczema who had trouble sleeping because of their condition. The goal was to see if the cream could help them sleep longer and better. The study was stopped early, but it involved 47 particip…

This early-stage study tested the safety and how the body handles the experimental drug INCB000631 in 24 healthy adults. Participants received either the drug or a placebo by mouth. The trial was terminated, so final results may not be available. It was not designed to treat any …